The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy

Abstract Radiotherapy is a non-invasive standard treatment for prostate cancer (PC). However, PC develops radio-resistance, highlighting a need for agents to improve radiotherapy response. Canagliflozin, an inhibitor of sodium-glucose co-transporter-2, is approved for use in diabetes and heart failu...

Full description

Bibliographic Details
Main Authors: Amr Ali, Bassem Mekhaeil, Olga-Demetra Biziotis, Evangelia E. Tsakiridis, Elham Ahmadi, Jianhan Wu, Simon Wang, Kanwaldeep Singh, Gabe Menjolian, Thomas Farrell, Aruz Mesci, Stanley Liu, Tobias Berg, Jonathan L. Bramson, Gregory R. Steinberg, Theodoros Tsakiridis
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Communications Biology
Online Access:https://doi.org/10.1038/s42003-023-05289-w

Internet

https://doi.org/10.1038/s42003-023-05289-w

Similar Items